Business Context and Reporting Period
This Form 8-K is a current report filed by Akers Biosciences, Inc. (the "Company") on November 11, 2015. The filing discloses a corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or operational metrics.
Material Changes
The material change reported is the appointment of Dr. Raza Bokhari as a director of the Company, effective immediately on November 11, 2015. The Board cited Dr. Bokhari's over 24 years of experience in healthcare senior management, including roles as CEO and Chairman at Lakewood Pathology Associates Inc., Parkway Clinical Laboratories, and Rosetta Genomics.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. It confirms there are no related party transactions associated with this appointment and no family relationships between Dr. Bokhari and current officers or directors.
Investor Verification Checklist
- Verify Dr. Raza Bokhari's current roles and potential conflicts of interest with competitors or suppliers.
- Review the attached Press Release (Exhibit 99.1) for additional context on the strategic rationale for this appointment.
- Check subsequent filings for any changes to the Board's composition or committee assignments.